Construction and Validation of a Prognostic Signature based on Anoikis- related lncRNAs in Lung Adenocarcinoma

Abstract Background Lung adenocarcinoma (LUAD) is the most prevalent form of lung cancer, with high mortality and poor prognosis. Anoikis, a type of programmed cell apoptosis, plays a vital role in the progression of tumors. Herein, we established a signature based on anoikis-related lncRNAs to predict the prognosis of LUAD patients. Method Genomic and clinical data were downloaded from the TCGA database. Coexpression analysis and Cox regression were conducted to establish the prognostic signature. Kaplan–Meier curves and ROC curves were used to validate the accuracy of the model, and a nomogram based on the signature was constructed. Subsequently, gene set enrichment analysis, immune analysis and drug sensitivity analysis were performed. Result Nine anoikis-related lncRNAs (AC090912.1, LINC00707, AC026355.2, FOCAD-AS1, LINC00460, LINC01117, AC068228.1, AP000346.1 and LINC01537) were obtained to develop a prognostic signature. The K-M curves showed that the high-risk group was correlated with worse overall survival, progression-free survival and disease-specific survival. The area under the ROC curves for 1-, 3-, and 5-year overall survival (0.722, 0.704 and 0.709, respectively) and the C-index demonstrated that the signature has higher predictive value than clinical factors. Functional enrichment analysis showed that lncRANs participated in tumor progression. Patients in the low-risk group had a better prognosis, more immune cell infiltration, and higher immune scores. We also observed different sensitivities to anticancer drugs in the two groups, which can guide treatment. Conclusion We developed and estimated a novel anoikis-related lncRNA signature that may be used to predict the prognosis of LUAD patients.